Research that Identifies
Undiscovered Value in the MicroCap Market


Nexeon Medsystems, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Updated Research Report (Dated 09/05/2018)

Symbol: NXNN
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $12.00
Time Horizon: 12 Months
Rating Established: January 9, 2018
Price When Established: $1.01
Most Recent Report: September 5, 2018
Price When Issued: $6.50

What's New

Nexeon Medsystems Announces $830,000 Grant Receipt

On September 25, 2018, Nexeon Medsystems announced it received an $830,000 grant from the National Institute of Neurological Disorders and Stroke (NINDS). The grant award, received through its subsidiary in Puerto Rico.

NINDS intends to fund $1.5 million over three-years, subject to annual review and approval, with the remaining funds directed towards clinical evaluation of the company’s software.

Company Description

Nexeon Medsystems, Inc., headquartered in Dallas, TX, is a global medical device company focused on providing neurostimulation products to improve the quality of life for patients suffering from neurological diseases. NXNN’s Belgian-based Medi-Line subsidiary provides global medical device outsource manufacturing solutions for existing customers and long term supply contracts with Fortune 50 companies.

Company Reports

Updated Research Report (Dated September 5, 2018)

Updated Research Report (Dated June 8, 2018)

Updated Research Report (Dated May 4, 2018)

Initial Research Report (Dated January 9, 2018)


Please view our current disclosure and disclaimer on our most recent research report.